Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
NCT ID: NCT07022496
Last Updated: 2025-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
120 participants
INTERVENTIONAL
2023-04-26
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
NCT01248468
The Effects of Caffeine Withdrawal on Migraine
NCT03022838
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine
NCT01629329
Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack
NCT01730326
Caffeine/Propranolol Intervention for Acute Migraine
NCT01080677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caffeine group
Caffeine group added to standard treatment
Caffeine (200 mg)
caffeine tablets
triptans
Sumatriptan
NSAID (Nonsteroidal anti-inflammatory drugs)
Aspirin 250 mg, 81 mg, 75 mg
Paracetamol (acetaminophen)
Paracetamol 250 mg
Control group
Standard treatment (NSAIDS, Triptans, or Acetaminophen)
triptans
Sumatriptan
NSAID (Nonsteroidal anti-inflammatory drugs)
Aspirin 250 mg, 81 mg, 75 mg
Paracetamol (acetaminophen)
Paracetamol 250 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Caffeine (200 mg)
caffeine tablets
triptans
Sumatriptan
NSAID (Nonsteroidal anti-inflammatory drugs)
Aspirin 250 mg, 81 mg, 75 mg
Paracetamol (acetaminophen)
Paracetamol 250 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nourhan Nader
Assistant lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ainshams university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MD87/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.